Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
ULTIMATE I and II pooled <i>post hoc</i> analyses demonstrated a consistent NEDA benefit among ublituximab-treated participants across treatment epochs and key participant subpopulations.
Authors
- Hari P. Miskin
- Bruce Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
- Edward Fox (ORCID: https://orcid.org/0000-0003-0347-1839)
- Krzysztof Selmaj (ORCID: https://orcid.org/0000-0003-1213-7218)
- Derrick Robertson (ORCID: https://orcid.org/0000-0001-8993-0981)
- Hans‐Peter Hartung (ORCID: https://orcid.org/0000-0002-0614-6989)
- Enrique Álvarez (ORCID: https://orcid.org/0000-0001-5854-9643)
- Daniel Wynn (ORCID: https://orcid.org/0000-0002-7214-8552)
- Lawrence Steinman (ORCID: https://orcid.org/0000-0002-2437-2250)
- Karthik Bodhinathan
- Koby Mok
- Peiqing Qian (ORCID: https://orcid.org/0000-0003-4774-7788)
- Sibyl Wray
- Yihuan Xu
Institutions
- The University of Sydney (AU)
- University of California, San Francisco (US)
- University of South Florida (US)
- Swedish Medical Center (US)
- HOPE Clinic (US)
- Consultants in Neurology (US)
- CDG Therapeutics (United States) (US)
- Heinrich Heine University Düsseldorf (DE)
- University of Warmia and Mazury in Olsztyn (PL)
- University of Colorado Anschutz Medical Campus (US)
- Palacký University Olomouc (CZ)
- Medical University of Vienna (AT)
- Stanford University (US)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3389/fneur.2024.1473284
- Citations
- 6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.55
Funders
- TG Therapeutics